Are Lash Growth Serums Safe? Bimatoprost, Cosmetic Prostaglandin Serums and What Regulators Found
SafeRxPills Pharmacy Team
Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.

Bimatoprost Eyelash Serum Safety: What You Need to Know Before Using It | SafeRxPills - pharmacy guide
In this article (22 sections)
Lash growth serums fall into two very different groups. Some contain bimatoprost or a chemical cousin of it, prostaglandin analogues that do change how lashes grow and carry known side effects, including a possible permanent darkening of the iris. Others contain peptides, oils and conditioners with little measurable effect and a much smaller list of risks. The trouble is that the two groups often look the same on a shelf, and testing has found prostaglandin analogues in products sold as cosmetics, sometimes without them being declared.
This page is a reference on lash serum safety. It sets out what the prescribing information for Latisse (bimatoprost 0.03%, the brand the FDA approved for sparse eyelashes; FDA-approved generics also exist) says about benefits and risks, what is in cosmetic serums, and what the FDA, Health Canada, the European Commission's scientific committee, France's ANSES and other regulators have found and done. Every number comes from a label, a regulator page or a published study, listed at the end.
The short answer
Prostaglandin-analogue serums work: in the Latisse trial, 78% of adults had a visible lash improvement after 16 weeks, against 18% on a dummy solution. They are also drugs, with side effects that include itching and redness (under 4% of trial patients), darkening of the eyelid skin (reversible in most people), brown darkening of the iris that is likely to be permanent, hair growth where the liquid touches skin, and, in reports after approval, loss of fat around the eye. They can interfere with glaucoma eye drops.
Cosmetic serums that contain prostaglandin analogues carry the same kinds of risk without a medicine's controls. Health Canada prohibits prostaglandins and their analogues in cosmetics. In 2026 the EU's scientific committee concluded that none of the three analogues it assessed could be considered safe in lash and brow cosmetics, and the European Commission has drafted a ban. Prostaglandin-free serums are lower risk but have little evidence that they grow lashes.
Two kinds of lash serum
| Prescription bimatoprost (Latisse and generics) | Cosmetic serum with a prostaglandin analogue | Prostaglandin-free cosmetic serum | |
|---|---|---|---|
| Active ingredient | Bimatoprost 0.03% | Isopropyl cloprostenate, dechloro dihydroxy difluoro ethylcloprostenolamide (also called ethyl tafluprostamide), methylamido dihydro noralfaprostal, or undeclared bimatoprost | Peptides, panthenol, castor oil, amino acids, biotin and similar |
| Grows lashes in trials | Yes, in a controlled trial on the label | Not tested to medicine standards | Little published evidence |
| Regulated as | Prescription medicine (FDA approval December 2008) | Sold as cosmetics; prohibited in Canadian cosmetics; EU ban drafted in 2026 | Cosmetic |
| Known risks | Listed in the prescribing information | Similar effects reported, not fully characterised | Mainly irritation or allergy to ingredients |
How prostaglandin analogues grow lashes
Bimatoprost is also the active ingredient of Lumigan, an eye drop that lowers pressure in glaucoma. Lash growth is a listed side effect of those drops: the UK Lumigan product information reports that in trials of the 0.3 mg/mL (0.03%) drops, growth of eyelashes was reported in up to 45% of patients in the first year. Latisse uses the same molecule at 0.03%, applied to the skin of the upper eyelid instead of into the eye. The Latisse prescribing information says the exact mechanism is unknown, but lash growth "is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase".
Cosmetic prostaglandin analogues such as isopropyl cloprostenate are chemically related molecules. The European Commission's scientific committee (SCCS) described them in 2026 as having "potent pharmacological activity" even at low concentrations. That is the core of the safety question: if a cosmetic works as well as a medicine, it is likely acting like one.
What the Latisse trial showed
The US approval rests on a multicentre, double-masked, randomised trial of 278 adults with sparse lashes (hypotrichosis), treated for 16 weeks. The main measure was at least a 1-grade improvement on a 4-point Global Eyelash Assessment scale.
| Week | Latisse 0.03% (n=137) | Vehicle (n=141) |
|---|---|---|
| 1 | 7 (5%) | 3 (2%) |
| 4 | 20 (15%) | 11 (8%) |
| 8 | 69 (50%) | 21 (15%) |
| 12 | 95 (69%) | 28 (20%) |
| 16 (main result) | 107 (78%) | 26 (18%) |
| 20 (4 weeks after stopping) | 103 (79%) | 27 (21%) |
Measured by digital image analysis at week 16, lashes on Latisse were on average 1.4 mm (25%) longer, 106% fuller and 18% darker, against 0.1 mm (2%), 12% and 3% on vehicle. The label says effects started to return toward baseline in the 4 weeks after stopping, and that lash growth is expected to return to its pre-treatment level once treatment stops.
| Change at week 16 | Latisse 0.03% | Vehicle |
|---|---|---|
| Length | +1.4 mm (25%) | +0.1 mm (2%) |
| Fullness / thickness | +0.7 mm² (106%) | +0.1 mm² (12%) |
| Darkness (intensity score) | -20.2 (18% darker) | -3.6 (3% darker) |
Side effects reported in trials
The prescribing information lists the most frequent adverse reactions as eye itching, eye redness (conjunctival hyperemia), skin darkening, eye irritation, dry eye symptoms and redness of the skin around the eye. Each occurred in less than 4% of patients. Other reactions seen in trials included a foreign body sensation, abnormal hair growth and darker iris pigment.
Reports collected after approval, where the frequency cannot be estimated, add: dry eyelid skin, eye and eyelid swelling, styes, local allergic reactions, increased tearing, temporary loss or breakage of lashes, ingrowing lashes (trichiasis), rash, skin discoloration, flaking eyelid skin, blurred vision, and changes linked to loss of fat around the eye (see below). For allergy eye drops themselves, such as olopatadine (Pataday), see our olopatadine eye drops guide.
Iris colour change: the effect that may not reverse
The label is direct: "Patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent." The change comes from more melanin in existing pigment cells. It may not be noticeable for several months to years. It typically starts around the pupil and spreads outwards, so a blue, green, grey or hazel iris can become partly or fully browner. The long-term effects of the extra pigment are not known.
Iris darkening is best documented with glaucoma drops put into the eye, but it is listed for Latisse as well, and it is the effect regulators highlight for cosmetic serums. France's ANSES described a case reported in February 2025: a young woman who applied an isopropyl cloprostenate serum to her upper lashes daily for five months found that her left eye had become significantly darker.
Darkening of the eyelid skin
Bimatoprost can darken the skin around the eye and the lashes themselves. The label says the pigmentation is expected to increase as long as the drug is used, and has been reported to be reversible after stopping in most patients. A 2017 case report described periocular discoloration in a 32-year-old woman using an isopropyl cloprostenate serum, which gradually faded after she stopped.
Fat loss around the eye
Prostaglandin analogues used for glaucoma are known to cause a group of changes called prostaglandin-associated periorbitopathy: loss of fat around the eye, a deeper upper eyelid crease and a hollow look. The Latisse label lists, from postmarketing reports, "periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis". For the glaucoma drops, the UK Lumigan product information says these changes are typically mild, can start as early as one month into treatment, may affect the field of vision without the person noticing, and have been partially or fully reversible after stopping or switching. Its warnings section adds that some of these changes may be permanent, and may lead to impaired field of vision and differences in appearance between the eyes when only one eye is treated.
The same pattern has been described with cosmetic serums. A 2022 report in Aesthetic Surgery Journal described a 35-year-old woman who developed thin, wrinkled, darker skin and hollowing around the eyes after 10 months of an isopropyl cloprostenate lash serum, which reversed 6 months after stopping. In the same paper, an informal study of 15 photo pairs, blinded graders scored manufacturers' own before-and-after photos higher for signs of fat loss in prostaglandin-analogue serum users than in users of other serums or false lashes. ANSES's case also involved fat loss around both eyes.
Hair growth outside the lash line and uneven lashes
Hair can grow wherever the solution repeatedly touches skin. The label tells users to apply only to the upper eyelid margin at the base of the lashes, not the lower lid, and to blot any excess so it does not run onto the cheek. It also warns that the two eyes may end up different in lash length, thickness, colour, number or direction of growth. These lash changes are likely to reverse after stopping.
Eye pressure and glaucoma drops
Bimatoprost lowers eye pressure. In the Latisse trials the reduction was not large enough to cause concern on its own. The issue is people already using a prostaglandin eye drop for glaucoma or high eye pressure, such as Lumigan or latanoprost eye drops. Exposure to more than one dose of bimatoprost a day can reduce the pressure-lowering effect, so adding a lash serum "may interfere with the desired reduction in IOP".
The label says patients on pressure-lowering medicines should not use Latisse without talking to their doctor first, and should have their eye pressure monitored. The same logic applies to any cosmetic serum containing a prostaglandin analogue, which is one reason the FDA gave when it acted against a bimatoprost lash product in 2007.
Eye inflammation, macular swelling and infection
- Inflammation: use with caution in active eye inflammation such as uveitis, which may get worse.
- Macular oedema: swelling at the back of the eye has been reported with bimatoprost glaucoma drops. Caution is advised after cataract surgery with a torn posterior lens capsule, in people without a natural lens, and in anyone with other risk factors.
- Contamination: the bottle tip must not touch any surface, and each sterile applicator is used on one eye only and then thrown away, because reuse raises the risk of infection. Bacterial keratitis has been reported with multi-dose eye products.
- New eye problems: after an eye injury, infection, surgery, a sudden drop in vision, or conjunctivitis or eyelid reactions, users should ask a doctor straight away whether to continue.
Contact lenses
Latisse contains the preservative benzalkonium chloride, which can be absorbed by soft contact lenses and discolour them. Lenses should be removed before applying and can go back in after 15 minutes.
Pregnancy and breastfeeding
There are no adequate studies of Latisse in pregnant women. The label notes no increase in birth defects or miscarriage in postmarketing experience, but in animal studies oral bimatoprost at many times the human exposure (at least 33 times in mice and 94 times in rats) caused abortion and early delivery, and at 41 times or more it shortened pregnancy and increased fetal and pup deaths in rats. The label says Latisse should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether it passes into human milk.
For cosmetic analogues the gap is larger. The SCCS based its 2026 conclusion partly on "the lack of acceptable data that would make it possible to exclude any potential adverse effects resulting from reproductive/developmental toxicity", and it stressed this point because most users are likely to be women of child-bearing age. Anyone pregnant, trying to conceive or breastfeeding should discuss any prostaglandin lash product with a doctor first.
Children and teenagers
Latisse was studied for 16 weeks in children and teenagers aged 5 to 17, and no new safety issues were seen. Results varied by group:
| Group | Latisse | Vehicle |
|---|---|---|
| Teenagers 15 to 17 with sparse lashes (n=40) | 19/26 (73%) | 1/14 (7%) |
| After chemotherapy, ages 5 to 17 (n=16) | 11/13 (85%) | 3/3 (100%) |
| Alopecia areata, ages 5 to 17 (n=15) | 4/9 (44%) | 2/6 (33%) |
Share with at least a 1-grade lash improvement at month 4. The groups after chemotherapy and with alopecia areata were small, and neither showed a benefit over vehicle: after chemotherapy lashes regrew in the vehicle group too, and in alopecia areata the difference (11%) had a 95% confidence interval from -39% to 61%.
What is inside cosmetic lash serums
Ingredient lists on cosmetic serums use INCI names, which rarely sound like drugs. Prostaglandin analogues found in cosmetic lash and brow products include:
- Isopropyl cloprostenate
- Dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE), also called ethyl tafluprostamide
- Methylamido dihydro noralfaprostal (MDN)
- Bimatoprost and norbimatoprost (bimatoprost is a prescription drug ingredient)
Market surveys show how common they are. A Japanese laboratory study of 64 serums bought online from 34 websites found bimatoprost in 4, three of which did not declare it on the label, and other prostaglandin F2 alpha analogues in 8 products. A French review of 79 lash products published in 2026 found that about 30% listed a prostaglandin analogue, most often DDDE or isopropyl cloprostenate. In Germany, a 2017 survey by federal and state food safety authorities, discussed by the BfR cosmetics commission in 2018, found four different analogues in eight lash products at 0.0006% to 0.022%.
Undeclared bimatoprost matters most, because a person using glaucoma drops, or someone who is pregnant, cannot make an informed choice about an ingredient that is not listed.
What regulators have found and done
| Date | Regulator | Action or finding |
|---|---|---|
| November 2007 | US FDA | US Marshals seized 12,682 tubes of Age Intervention Eyelash (Jan Marini Skin Research, California). The FDA said the product contained bimatoprost, was an unapproved and misbranded drug because it was promoted to grow lashes, and was an adulterated cosmetic. It warned of a higher risk of optic nerve damage, which may lead to decreased vision and possibly blindness, when used alongside glaucoma drugs, and of macular oedema and uveitis, which may also decrease vision. |
| December 2008 | US FDA | Approved Latisse (bimatoprost 0.03%) as a prescription treatment for sparse eyelashes. |
| June 2015 (proposed), later listed | Health Canada | Proposed adding prostaglandins and their analogues to the Cosmetic Ingredient Hotlist as prohibited, "due to their presence on the Prescription Drug List and their therapeutic functions". The current Hotlist lists "Prostaglandins, their salts and derivatives and their analogs", with bimatoprost and cloprostenol among the examples. |
| April 2018 | Germany, BfR Commission for Cosmetic Products | Said the side-effect profile "cannot be accepted for a cosmetic product", saw an urgent need for action, and asked for an EU assessment with the aim of a ban in cosmetics. |
| February 2022 | EU Scientific Committee on Consumer Safety (SCCS/1635/21) | Was not able to conclude on the safety of isopropyl cloprostenate and ethyl tafluprostamide in cosmetics. |
| December 2024 | UK Office for Product Safety and Standards | Published an independent research report on prostaglandin analogues in cosmetics, with a literature review, market survey and laboratory testing. |
| December 2025 / January 2026 | France, ANSES | Warned that lash serums with prostaglandin-like substances can cause irreversible iris darkening and fat loss around the eye, citing a cosmetovigilance case. |
| February 2026 | EU SCCS (SCCS/1680/25) | Concluded that none of isopropyl cloprostenate, methylamido dihydro noralfaprostal and DDDE "can be considered safe for use in cosmetic products intended for promoting the growth of eyelashes and eyebrows". |
| July to September 2026 | European Commission | Notified the WTO of, and sent to the Council, a draft regulation adding "prostaglandines and their analogues" to Annex II (prohibited substances) of the Cosmetics Regulation. Under the draft, products could not be placed on the EU market 12 months after it takes effect, or sold at all after 24 months. As of October 2026 it had not been adopted. |
We found no US rule that bans prostaglandin analogues in cosmetics by name. The FDA's position is that a product claiming to grow lashes is a drug, whatever it is called, and its page on drug claims in cosmetics lists "eyelash growth" among them.
Prostaglandin-free serums: lower risk, weaker evidence
Most cosmetic lash serums do not contain prostaglandin analogues. The French survey found the rest were mainly formulated with ingredients such as castor oil, amino acids, panthenol, peptides and peptide derivatives. These are unlikely to darken the iris or cause fat loss around the eye, but they can still irritate or cause an allergic reaction, particularly near the eye.
The weakness is evidence. We found no controlled trial of a peptide or oil serum that measured lash growth to the standard of the Latisse trial. Our review of The Ordinary's multi-peptide lash serum looks at what one popular product's own data shows. Conditioning serums may make lashes look healthier and break less, which is not the same as growing them.
How to check a lash serum before you use it
- Read the ingredient list for any of the names above. A simple rule: treat any ingredient name containing "prost" (for example cloprostenate, tafluprostamide, noralfaprostal, bimatoprost) as a prostaglandin analogue.
- Be wary of strong growth claims. A cosmetic promising dramatic growth in weeks may contain a prostaglandin analogue, declared or not. In the US, a growth claim alone makes the product a drug in the FDA's view.
- Prefer products with a full ingredient list and a traceable maker. In the Japanese testing of serums bought online, three of the four products containing bimatoprost did not declare it.
- If you use any glaucoma or eye-pressure drops, do not use a prostaglandin serum without your eye doctor's agreement. Our overview of glaucoma eye drop types shows which drops are prostaglandin analogues.
- If you want a serum that grows lashes, the evidence-based option is bimatoprost under medical supervision, where you know the dose and the risks.
Who should not use a prostaglandin lash serum
- Anyone allergic to bimatoprost or any ingredient (the only formal contraindication on the Latisse label).
- People using prostaglandin eye drops for glaucoma or high eye pressure, unless their eye doctor agrees and monitors pressure.
- People with active eye inflammation such as uveitis, or with risk factors for macular swelling, unless a doctor advises otherwise.
- Anyone with light-coloured eyes who is not prepared to accept a possible permanent change in iris colour.
- People who are pregnant, trying to conceive or breastfeeding, without medical advice.
- Anyone with a current eye infection, recent eye surgery or eye injury, until a doctor says it is safe.
If you get irritation or notice changes
- Itching, redness or stinging: stop, and wait for it to settle. If it persists, see a doctor or pharmacist.
- Eyelid darkening, hair growth on the cheek, hollow-looking eyes: stop the serum and tell a doctor. Lid darkening and lash changes often fade over months, and the fat-loss case report reversed within 6 months of stopping.
- Any change in iris colour: stop and see an eye doctor. This change may not reverse.
- Eye pain, a sudden change in vision, swelling or discharge: seek medical advice the same day.
- Report the reaction. In the US this is FDA MedWatch. In the UK, report reactions to a medicine such as bimatoprost to the MHRA Yellow Card scheme, and problems with a cosmetic to Trading Standards through Citizens Advice. In France, cosmetic reactions go to ANSES cosmetovigilance. Reports are how regulators found these problems.
For how to apply bimatoprost correctly, see our step-by-step label method for applying Careprost. Timelines are in Careprost results week by week, and off-label brow use is covered in bimatoprost for eyebrows.
Where SafeRxPills fits
This note is separate from the reference material above. SafeRxPills sells bimatoprost 0.03% products made in India, such as Careprost 3 mL and a bimatoprost 0.03% lash solution sold as a Latisse alternative. These are not FDA-approved (they are not the FDA-approved US generics mentioned above). Bimatoprost is a prescription medicine in the US, and every risk on this page applies to these products. US legal status is covered in is Careprost legal in the USA, and the differences from the US brand in Careprost vs Latisse. Prices per bottle for US buyers are on our Careprost buying page for the US. More guides are on our eyelash growth page.
Sources
- LATISSE (bimatoprost ophthalmic solution) 0.03% prescribing information. AbbVie (Allergan). DailyMed SPL version 25, published 23 December 2025. Sections 4, 5, 6, 8, 12 and 14 (Tables 1 to 3); Drugs@FDA NDA 022369 (approved December 2008).
- US Food and Drug Administration. Alert on Age Intervention Eyelash, news release 16 November 2007 (seizure of 12,682 tubes, Jan Marini Skin Research).
- US Food and Drug Administration. Warning letters that address drug claims made for products marketed as cosmetics (eyelash growth).
- Health Canada. Consultation on proposed changes to the Cosmetic Ingredient Hotlist, 26 June 2015; Cosmetic Ingredient Hotlist, prohibited ingredients (accessed October 2026).
- Bundesinstitut für Risikobewertung. Minutes of the 21st meeting of the BfR Commission for Cosmetic Products, 18 April 2018, item 5.
- Scientific Committee on Consumer Safety. Opinion on prostaglandins and prostaglandin analogues used in cosmetic products, SCCS/1635/21, adopted 3 February 2022.
- Scientific Committee on Consumer Safety. Opinion on prostaglandin analogues MDN, IPCP and DDDE, SCCS/1680/25, adopted 2 February 2026.
- European Commission. Draft Commission Regulation amending Regulation (EC) No 1223/2009, D(2026) 117774, Council document 13462/26 ADD 1, 22 September 2026; WTO notification G/TBT/N/EU/1219.
- ANSES. Eyelash growth serums may change your eye colour (English version dated 9 January 2026).
- Office for Product Safety and Standards. Prostaglandin analogues in cosmetics, published 5 December 2024.
- Jamison et al. Do prostaglandin analogue lash lengtheners cause eyelid fat and volume loss? Aesthetic Surgery Journal. 2022. PMID 35700523.
- Horváth et al. Periocular discoloration after using a prostaglandin analog for eyelash enhancement. Journal of Cosmetic Dermatology. 2017. PMID 27595988.
- Rahman et al. Screening and quantification of undeclared PGF2α analogs in eyelash-enhancing cosmetic serums using LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2022. PMID 35882176.
- Couteau C, Coiffard L. Prostaglandin analogues in cosmetic products formulated for eyelash lengthening. Annales Pharmaceutiques Françaises. 2026. PMID 42269767.
- Lumigan 0.1 mg/mL eye drops, Summary of Product Characteristics (UK, emc), section 4.8, accessed October 2026.
This page is for information and does not replace advice from a doctor, pharmacist or eye specialist. Stop any lash product that causes eye symptoms and seek advice.
?Frequently Asked Questions
Are lash growth serums safe?
It depends on what is in them. Serums with bimatoprost or other prostaglandin analogues grow lashes but can cause eye redness and itching, eyelid darkening, fat loss around the eye and iris darkening that is likely to be permanent. Prostaglandin-free serums carry fewer risks but have little evidence of growing lashes.
Can bimatoprost change your eye colour?
Yes. The Latisse prescribing information warns of increased brown iris pigmentation that is likely to be permanent. It may take months to years to notice, and usually spreads outward from the pupil. It matters most for people with blue, green, grey or hazel eyes.
Is eyelid darkening from bimatoprost permanent?
Usually not. The Latisse label says darkening of the skin around the eye increases while the drug is used and has been reported to reverse after stopping in most patients.
Do lash serums cause fat loss around the eyes?
Prostaglandin analogues can. The Latisse label lists postmarketing reports of periorbital fat atrophy with a deeper eyelid crease and drooping lid, and a 2022 case report described hollowing after 10 months of an isopropyl cloprostenate serum, which reversed 6 months after stopping.
Which lash serum ingredients are prostaglandin analogues?
Names to look for include isopropyl cloprostenate, dechloro dihydroxy difluoro ethylcloprostenolamide (also called ethyl tafluprostamide), methylamido dihydro noralfaprostal, bimatoprost and norbimatoprost. Any ingredient name containing "prost" is a warning sign.
Can I use a lash serum if I have glaucoma?
Not without your eye doctor. The Latisse label says people using prostaglandin drops such as Lumigan for eye pressure should only use it after consulting their doctor and should have their eye pressure monitored, because an extra daily dose can reduce the drops' pressure-lowering effect.
Are prostaglandin lash serums banned?
Health Canada lists prostaglandins and their analogues as prohibited in cosmetics. In the EU, the SCCS concluded in February 2026 that three analogues cannot be considered safe in lash and brow cosmetics, and the European Commission has drafted a ban that had not been adopted as of October 2026. In the US, the FDA treats products claiming to grow lashes as drugs.
How well does Latisse work?
In the label trial of 278 adults, 78% on Latisse had at least a 1-grade lash improvement at 16 weeks against 18% on vehicle. Lashes were on average 25% longer, 106% fuller and 18% darker. Effects begin to fade after stopping.
Can I use a bimatoprost lash serum while pregnant?
There are no adequate studies in pregnant women, and high oral doses caused abortion and early delivery in animal studies. The EU safety committee cited missing reproductive toxicity data for cosmetic analogues. Talk to a doctor before using any prostaglandin lash product while pregnant, trying to conceive or breastfeeding.
Do prostaglandin-free lash serums work?
There is little published evidence. Most contain ingredients such as peptides, panthenol, castor oil and amino acids. We found no controlled trial showing lash growth comparable to the Latisse trial. They may condition lashes and reduce breakage.
What should I do if a lash serum irritates my eyes?
Stop using it. See a doctor the same day for eye pain, vision changes, swelling or discharge, and see an eye doctor for any change in iris colour. Report the reaction to your regulator, such as FDA MedWatch in the US.
SafeRxPills Pharmacy Team
Pharmacist, Content, B.Pharm, M.Pharm, Rajiv Gandhi University
Pharmacist writing on antiparasitic, ophthalmic and dermatological generics. Focuses on what the regulatory labelling and published evidence actually support.
Comments (0)
Leave a Comment
No comments yet. Be the first to share your thoughts!
Related Articles

How Long Does Careprost Take to Work? Week by Week Results From the Latisse Trial
June 20, 2026

How to Apply Careprost and Latisse to Eyelashes: The Label Method, Step by Step
June 21, 2026

